Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs
Open Access
- 23 March 2022
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 257 (2) , 172-185
Abstract
Recent evidence indicates that RNA‐dependent RNA polymerase (RdRP) activity of human telomerase reverse transcriptase (hTERT) regulates expression of target genes and is directly involved in tumor formation in a telomere‐independent manner. Non‐canonical function of hTERT has been considered as a therapeutic target for cancer therapy. We have previously shown that hTERT phosphorylation at threonine 249 (p‐hTERT), which promotes RdRP activity, is an indicator of an aggressive phenotype and poor prognosis in liver and pancreatic cancers, using two cohorts with small sample sizes with polyclonal p‐hTERT antibody. To clarify the clinical relevance of p‐hTERT, we developed a specific monoclonal antibody and determined the diagnostic and prognostic value of p‐hTERT in cancer specimens using a large cohort. A monoclonal antibody for phosphorylated hTERT (p‐hTERT) at threonine 249 was developed and validated. The antibody was used for the immunohistochemical staining of formalin‐fixed, paraffin‐embedded specimens from 1523 cases of lung, colon, stomach, pancreatic, liver, breast, and kidney cancers. We detected elevated p‐hTERT expression levels in cases with a high mitotic activity, high pathological grade, and high nuclear pleomorphism. Elevated p‐hTERT expression was an independent prognostic factor for lung, pancreatic, and liver cancers. Furthermore, p‐hTERT expression was associated with immature and aggressive features, such as adenosquamous carcinoma (lung and pancreas), invasive type of cancer (lung), high serum alpha‐fetoprotein level (liver), and triple‐negative status (breast). In conclusion, RdRP activity indicated by p‐hTERT expression predicts aggressive cancer phenotypes in various types of cancer. Thus, p‐hTERT is a novel biomarker for the diagnosis of aggressive cancers with a poor prognosis. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- Japan Agency for Medical Research and Development (20cm0106473h0001, JP20am0101078, JP20ck0106403, JP21fk0210049)
This publication has 30 references indexed in Scilit:
- Involvement of Telomerase Reverse Transcriptase in Heterochromatin MaintenanceMolecular and Cellular Biology, 2014
- Adenosquamous Carcinoma of the Lung: Surgical Management, Pathologic Characteristics, and Prognostic ImplicationsThe Annals of Thoracic Surgery, 2013
- Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?Oncogene, 2012
- Maintenance of tumor initiating cells of defined genetic composition by nucleosteminProceedings of the National Academy of Sciences, 2011
- Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel diseaseGastroenterología y Hepatología, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- An RNA-dependent RNA polymerase formed by TERT and the RMRP RNANature, 2009
- Distribution and prognostic significance of human telomerase reverse transcriptase (hTERT) expression in giant-cell tumor of boneLaboratory Investigation, 2008
- Clinicopathological and molecular characteristics of gastric and colorectal carcinomas in the elderlyPathology International, 2007
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005